Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Frank Stephen Hodi, M.D.


This page shows the publications co-authored by Frank Hodi and Howard Kaufman.
Connection Strength

  1. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
    View in: PubMed
    Score: 0.196
  2. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016; 4:42.
    View in: PubMed
    Score: 0.173
  3. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15(12):1389-403.
    View in: PubMed
    Score: 0.155
  4. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.141
  5. Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16.
    View in: PubMed
    Score: 0.045
  6. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.